Clinical potential of oligonucleotide-based therapeutics in the respiratory system
详细信息 查看全文
- 作者：Sterghios A. Moschosa ; c ; sterghios.moschos@northumbria.ac.uk ; Louise Ushera ; Mark A. Lindsayb
- 关键词：AGO ; Argonaute ; ASO ; antisense oligonucleotide ; CCR3 ; C&ndash ; C chemokine receptor 3 ; CPP ; cell penetrating peptide ; COPD ; chronic obstructive pulmonary disease ; CD ; cluster designation ; GMCSF ; granulocyte monocyte-colony stimulating factor ; IL ; interleukin ; IL-&lsquo ; X&rsquo ; R ; Interleukin receptor number &lsquo ; X&rsquo ; LNA ; locked nucleic acid ; miRNA ; microRNA ; ncRNA ; non-coding RNA ; nt ; nucleotide ; PNA ; peptide nucleic acid ; PMO ; phosphorodiamidate morpholinos ; RISC ; RNA induced silencing c
- 刊名：Pharmacology & Therapeutics
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：169
- 期：Complete
- 页码：83-103
- 全文大小：1427 K
- 卷排序：169
文摘
The discovery of an ever-expanding plethora of coding and non-coding RNAs with nodal and causal roles in the regulation of lung physiology and disease is reinvigorating interest in the clinical utility of the oligonucleotide therapeutic class. This is strongly supported through recent advances in nucleic acids chemistry, synthetic oligonucleotide delivery and viral gene therapy that have succeeded in bringing to market at least three nucleic acid-based drugs. As a consequence, multiple new candidates such as RNA interference modulators, antisense, and splice switching compounds are now progressing through clinical evaluation. Here, manipulation of RNA for the treatment of lung disease is explored, with emphasis on robust pharmacological evidence aligned to the five pillars of drug development: exposure to the appropriate tissue, binding to the desired molecular target, evidence of the expected mode of action, activity in the relevant patient population and commercially viable value proposition.